Sign In
Buy IRWD
$3.24
-0.0400 (-1.22%)
At Close: Jun 03, 2026
Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion
10:32am, Tuesday, 13'th Jun 2023
Ironwood (IRWD) lead drug Linzess gets FDA approval for pediatric functional constipation The label expansion of the drug is expected to boost the company's sales.
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
09:54am, Monday, 12'th Jun 2023
Ironwood's drug Linzess is seeing its sales start to plateau. It could get an expanded indication for Linzess that delays a decline in revenue.
Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%
01:09pm, Tuesday, 23'rd May 2023
Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio.
Why Ironwood Pharmaceuticals Stock Bumped Higher Today
05:43pm, Monday, 22'nd May 2023
Investors cheered the gastrointestinal treatment specialist's latest asset buy. This, despite the fact that it's paying a more-than 40% premium, according to the terms of the deal.
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
09:43am, Monday, 22'nd May 2023
Ironwood Pharmaceuticals said Monday it will buy VectivBio for $1 billion. The deal sent VECT stock flying, while IRWD stock skidded.
Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion
07:46am, Monday, 22'nd May 2023
Ironwood Pharmaceuticals is paying $17 a share for the Swiss biotech company.
Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion
07:10am, Monday, 22'nd May 2023
Ironwood Pharmaceuticals Inc. IRWD, +2.45% said Monday it has agreed to acquire Swiss biotech VectivBio Holding AG VECT, +8.18% for $17 a share in cash, or a total of about $1 billion, net of VectivBi
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2023 Earnings Call Transcript
06:23pm, Saturday, 06'th May 2023
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - CEO Mike Shetzline
Ironwood Pharmaceuticals (IRWD) Surpasses Q1 Earnings and Revenue Estimates
10:41am, Thursday, 04'th May 2023
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.21 per share a year ago.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings during the 2023 Digestive Disease Week®
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
04:01pm, Monday, 27'th Feb 2023
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will participate in the following investor conferences: Cowen 4
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases
12:48pm, Friday, 17'th Feb 2023
Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2022 Earnings Call Transcript
01:03pm, Thursday, 16'th Feb 2023
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q4 2022 Earnings Conference Call February 16, 2023 8:30 AM ET Company Participants Matt Roache - Director, IR Thomas McCourt - CEO & Director Michael Shet
Ironwood Pharmaceuticals (IRWD) Misses Q4 Earnings and Revenue Estimates
09:47am, Thursday, 16'th Feb 2023
Ironwood (IRWD) delivered earnings and revenue surprises of -3.57% and 3.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA
09:02am, Tuesday, 14'th Feb 2023
With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2
